ES2180535T3 - Identificacion de un nuevo gen de tirosina quinasa receptora humana. - Google Patents

Identificacion de un nuevo gen de tirosina quinasa receptora humana.

Info

Publication number
ES2180535T3
ES2180535T3 ES92907369T ES92907369T ES2180535T3 ES 2180535 T3 ES2180535 T3 ES 2180535T3 ES 92907369 T ES92907369 T ES 92907369T ES 92907369 T ES92907369 T ES 92907369T ES 2180535 T3 ES2180535 T3 ES 2180535T3
Authority
ES
Spain
Prior art keywords
receptor
receptora
identification
human
new gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907369T
Other languages
English (en)
Inventor
Bruce Israel Terman
Miguel Eduardo Carrion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2180535T3 publication Critical patent/ES2180535T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTA UNA SECUENCIA DE DNA QUE CODIFICA UN NUEVO FACTOR DEL CRECIMIENTO HUMANO REFERENCIADA COMO QUINASA DE TIROSINA RECEPTORA DE TIPO III. TAMBIEN SE DESCRIBE LA SECUENCIA DE AMINOACIDO DEL RECEPTOR. EL RECEPTOR TIENE UNA SECUENCIA QUE ES SIMILAR A LOS DOMINIOS DE LAS QUINASAS DE TIROSINA RECEPTORAS DE TIPO III CONOCIDAS, PERO QUE ES UNICA EN SU SECUENCIA DE DOMINIO DE INSERCION DE LA QUINASA. EL RECEPTOR SE UNE ESPECIFICAMENTE AL FACTOR DEL CRECIMIENTO CELULAR ENDOTELIAL VASCULAR.
ES92907369T 1991-02-22 1992-02-20 Identificacion de un nuevo gen de tirosina quinasa receptora humana. Expired - Lifetime ES2180535T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65723691A 1991-02-22 1991-02-22

Publications (1)

Publication Number Publication Date
ES2180535T3 true ES2180535T3 (es) 2003-02-16

Family

ID=24636385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907369T Expired - Lifetime ES2180535T3 (es) 1991-02-22 1992-02-20 Identificacion de un nuevo gen de tirosina quinasa receptora humana.

Country Status (8)

Country Link
EP (1) EP0536350B1 (es)
AT (1) ATE221915T1 (es)
CA (1) CA2083401C (es)
DE (1) DE69232718T2 (es)
DK (1) DK0536350T3 (es)
ES (1) ES2180535T3 (es)
SG (1) SG49753A1 (es)
WO (1) WO1992014748A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
CA2128722A1 (en) * 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
DK1975181T3 (da) * 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6872699B2 (en) 1992-11-13 2005-03-29 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V. Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994021679A1 (en) 1993-03-25 1994-09-29 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
EP0751992B1 (en) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
PT868519E (pt) * 1995-12-18 2006-05-31 Sugen Inc Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
ATE489108T1 (de) 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP2284180B1 (en) 2003-03-03 2015-09-09 Dyax Corp. Uses of peptides that specifically bind HGF receptor (cMET)
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
DK1819358T3 (da) 2004-11-18 2014-10-27 Imclone Llc Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof

Also Published As

Publication number Publication date
SG49753A1 (en) 1998-06-15
EP0536350A1 (en) 1993-04-14
ATE221915T1 (de) 2002-08-15
DE69232718D1 (de) 2002-09-12
CA2083401C (en) 2003-03-25
EP0536350A4 (en) 1994-03-22
EP0536350B1 (en) 2002-08-07
DE69232718T2 (de) 2003-04-03
DK0536350T3 (da) 2002-09-02
WO1992014748A1 (en) 1992-09-03
CA2083401A1 (en) 1992-08-23

Similar Documents

Publication Publication Date Title
DK0536350T3 (da) Identifikation af et nyt humant receptor-tyrosinkinase-gen
IL191078A0 (en) POLYPEPTIDES WHICH BIND TO ErbB3 OR ErbB4 RECEPTOR PROTEIN TYROSINE KINASE OR BOTH, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS, METHOD FOR PRODUCTION AND USE OF SUCH POLYPEPTIDES
EA199800116A1 (ru) Пирролопиримидины и фармацевтические композиции, включающие эти соединения
CY2451B1 (en) Fused heterocyclic compunds as protein tyrosine kinase inhibitors.
DE69838334D1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
BRPI0009721B8 (pt) Inibidores de tirosina quinase de proteína cíclica
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
TR199900624T2 (xx) Proteinlerin y�ksek seviyede ekspresyonu.
NO307833B1 (no) Pyrimido[5,4-d]pyrimidiner, fysiologisk aksepterbare salter, legemidler inneholdende disse forbindelser og deres anvendelse
EA199900021A1 (ru) Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
DE69834852D1 (de) NL3 TIE Rezeptortyrosinekinase Ligandhomologe
DK0590071T3 (da) Hovedsagelig rene receptor-lignende TGF-BETA-1 bindende molekyler samt anvendelse deraf
NZ296638A (en) Ligands which bind to tie-2 (tyrosine kinase with ig and egf homology domains) receptors
TR200002015T2 (tr) Protein tirosin kinaz inhibitörleri olarak bisiklik heteroaromatik bileşikler.
DE69940808D1 (de) Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
PT100037A (pt) Processo de expressao-clonacao para detectar proteinas alvo para tirosina-quinases de receptores sonda polipeptidica e proteinas grb humanas
ATE324441T1 (de) Htk-ligand
FI972492L (fi) Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
ATE331791T1 (de) Phosphodiesterase 10
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
BR9910787A (pt) Métodos e composições úteis para modulação deangiogênese usando tirosina cinase src
DK0939769T3 (da) Vertebrat-Smoothened-proteiner